Fabrazyme 5 MG vials
Ended Awarded
- Contract number
- SPE2DB26FY19A
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,591
Award facts
- Contract value 100% obligated
- $1,591.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $1,591.18 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fabrazyme 5 mg vials. The award, issued on November 12, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that establishes multiple regional prime vendor contractors to supply pharmaceuticals and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with demonstrated performance across a diverse product portfolio including specialty biologics, branded and generic medications, vaccines, and emergency pharmaceuticals. The company's PPV-G GEN V contract, awarded November 13, 2025, carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. This delivery order for Fabrazyme, an enzyme replacement therapy used to treat Fabry disease, exemplifies the specialized pharmaceutical requirements the contractor fulfills for military medical operations.
Quick answers
Who was awarded contract SPE2DB26FY19A?
SPE2DB26FY19A was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DB26FY19A worth?
The government has obligated $1,591 on SPE2DB26FY19A.
Is contract SPE2DB26FY19A an order under another contract?
Yes. SPE2DB26FY19A is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB26FY19A competed?
The extent of competition for SPE2DB26FY19A was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award